First Time Loading...

Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 7.06 USD -1.26% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

FULC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. [ Read More ]

The intrinsic value of one FULC stock under the Base Case scenario is 3.06 USD. Compared to the current market price of 7.06 USD, Fulcrum Therapeutics Inc is Overvalued by 57%.

Key Points:
FULC Intrinsic Value
Base Case
3.06 USD
Overvaluation 57%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Fulcrum Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling FULC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Fulcrum Therapeutics Inc

Provide an overview of the primary business activities
of Fulcrum Therapeutics Inc.

What unique competitive advantages
does Fulcrum Therapeutics Inc hold over its rivals?

What risks and challenges
does Fulcrum Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Fulcrum Therapeutics Inc recently?

Summarize the latest earnings call
of Fulcrum Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Fulcrum Therapeutics Inc.

Provide P/S
for Fulcrum Therapeutics Inc.

Provide P/E
for Fulcrum Therapeutics Inc.

Provide P/OCF
for Fulcrum Therapeutics Inc.

Provide P/FCFE
for Fulcrum Therapeutics Inc.

Provide P/B
for Fulcrum Therapeutics Inc.

Provide EV/S
for Fulcrum Therapeutics Inc.

Provide EV/GP
for Fulcrum Therapeutics Inc.

Provide EV/EBITDA
for Fulcrum Therapeutics Inc.

Provide EV/EBIT
for Fulcrum Therapeutics Inc.

Provide EV/OCF
for Fulcrum Therapeutics Inc.

Provide EV/FCFF
for Fulcrum Therapeutics Inc.

Provide EV/IC
for Fulcrum Therapeutics Inc.

Show me price targets
for Fulcrum Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Fulcrum Therapeutics Inc?

How accurate were the past Revenue estimates
for Fulcrum Therapeutics Inc?

What are the Net Income projections
for Fulcrum Therapeutics Inc?

How accurate were the past Net Income estimates
for Fulcrum Therapeutics Inc?

What are the EPS projections
for Fulcrum Therapeutics Inc?

How accurate were the past EPS estimates
for Fulcrum Therapeutics Inc?

What are the EBIT projections
for Fulcrum Therapeutics Inc?

How accurate were the past EBIT estimates
for Fulcrum Therapeutics Inc?

Compare the revenue forecasts
for Fulcrum Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Fulcrum Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Fulcrum Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Fulcrum Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Fulcrum Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Fulcrum Therapeutics Inc with its peers.

Analyze the financial leverage
of Fulcrum Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Fulcrum Therapeutics Inc.

Provide ROE
for Fulcrum Therapeutics Inc.

Provide ROA
for Fulcrum Therapeutics Inc.

Provide ROIC
for Fulcrum Therapeutics Inc.

Provide ROCE
for Fulcrum Therapeutics Inc.

Provide Gross Margin
for Fulcrum Therapeutics Inc.

Provide Operating Margin
for Fulcrum Therapeutics Inc.

Provide Net Margin
for Fulcrum Therapeutics Inc.

Provide FCF Margin
for Fulcrum Therapeutics Inc.

Show all solvency ratios
for Fulcrum Therapeutics Inc.

Provide D/E Ratio
for Fulcrum Therapeutics Inc.

Provide D/A Ratio
for Fulcrum Therapeutics Inc.

Provide Interest Coverage Ratio
for Fulcrum Therapeutics Inc.

Provide Altman Z-Score Ratio
for Fulcrum Therapeutics Inc.

Provide Quick Ratio
for Fulcrum Therapeutics Inc.

Provide Current Ratio
for Fulcrum Therapeutics Inc.

Provide Cash Ratio
for Fulcrum Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Fulcrum Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Fulcrum Therapeutics Inc?

What is the current Free Cash Flow
of Fulcrum Therapeutics Inc?

Financials

Balance Sheet Decomposition
Fulcrum Therapeutics Inc

Current Assets 242.2m
Cash & Short-Term Investments 236.2m
Receivables 2.2m
Other Current Assets 3.7m
Non-Current Assets 15.5m
PP&E 12.4m
Other Non-Current Assets 3.1m
Current Liabilities 13.7m
Accounts Payable 2.8m
Accrued Liabilities 10.5m
Other Current Liabilities 396k
Non-Current Liabilities 8.8m
Other Non-Current Liabilities 8.8m
Efficiency

Earnings Waterfall
Fulcrum Therapeutics Inc

Revenue
2.8m USD
Operating Expenses
-113.5m USD
Operating Income
-110.7m USD
Other Expenses
13.3m USD
Net Income
-97.3m USD

Free Cash Flow Analysis
Fulcrum Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

FULC Profitability Score
Profitability Due Diligence

Fulcrum Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROE is Increasing
ROIC is Increasing
Negative 1-Year Revenue Growth
20/100
Profitability
Score

Fulcrum Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

FULC Solvency Score
Solvency Due Diligence

Fulcrum Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Fulcrum Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FULC Price Targets Summary
Fulcrum Therapeutics Inc

Wall Street analysts forecast FULC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FULC is 13.52 USD with a low forecast of 5.05 USD and a high forecast of 19.95 USD.

Lowest
Price Target
5.05 USD
28% Downside
Average
Price Target
13.52 USD
91% Upside
Highest
Price Target
19.95 USD
183% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

FULC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

FULC Price
Fulcrum Therapeutics Inc

1M 1M
-30%
6M 6M
+97%
1Y 1Y
+182%
3Y 3Y
-38%
5Y 5Y
-48%
10Y 10Y
-48%
Annual Price Range
7.06
52w Low
2.48
52w High
12
Price Metrics
Average Annual Return -4.1%
Standard Deviation of Annual Returns 43.58%
Max Drawdown -93%
Shares Statistics
Market Capitalization 437.1m USD
Shares Outstanding 61 935 200
Percentage of Shares Shorted 4.51%

FULC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

437.1m USD

Dividend Yield

0%

Description

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).

Contact

MASSACHUSETTS
Cambridge
26 Landsdowne St
+16176518851.0
http://www.fulcrumtx.com/

IPO

2019-07-18

Employees

104

Officers

CEO, President & Director
Mr. Alexander C. Sapir
Founder
Dr. Danny Reinberg
Chief Financial Officer
Mr. Alan A. Musso C.M.A., CPA
Controller & Principal Accounting Officer
Mr. Gregory Tourangeau
Chief Scientific Officer
Dr. Jeffrey W. Jacobs Ph.D.
Senior VP, Chief Legal Officer & Corporate Secretary
Mr. Curtis G. Oltmans J.D.

See Also

Discover More
What is the Intrinsic Value of one FULC stock?

The intrinsic value of one FULC stock under the Base Case scenario is 3.06 USD.

Is FULC stock undervalued or overvalued?

Compared to the current market price of 7.06 USD, Fulcrum Therapeutics Inc is Overvalued by 57%.